Acute Myeloid Leukemia: Advances in Initial Therapy

Daniel Pollyea, MD, MS, discusses the current treatment options for acute myeloid leukemia.

EP. 1: Biomarker Testing in AML

September 24th 2021

Daniel Pollyea, MD, MS, explains the risk factors for acute myeloid leukemia, the importance of biomarker testing, and the challenges that prevent every patient from being tested.

EP. 2: Frontline Treatment Options in AML

September 24th 2021

A hematologist details the frontline treatment options and goals in acute myeloid leukemia and describes venetoclax.

EP. 3: VIALE-A Trial: Acute Myeloid Leukemia

September 24th 2021

Dr. Pollyea breaks down data from the recent VIALE-A phase III clinical trial.

EP. 4: Considerations in Choosing Venetoclax for AML

September 24th 2021

An expert describes the considerations in choosing to treat acute myeloid leukemia patients with venetoclax.

EP. 5: Future of AML Management

September 24th 2021

Daniel Pollyea, MD, MS, discusses the unmet needs and future management strategies of acute myeloid leukemia.